ROLE OF EARLY SECOND TURBT IN DETECTION OF RECURRENCE AND DISEASE PROGRESSION IN T1 TCC BLADDER

Dr Vikas Dhawan, Dr Shailesh C Karan, Dr Gurjot Singh, Dr Sunaina Dhawan

Abstract


Introduction : Majority of the Bladder cancers are non-muscle invasive T1 tumours which have a high propensity of recurrence and at times may be under staged during the initial trans-urethral resection. This study aims to evaluate the role of early second transurethral resection of the bladder tumour (TURBT) in timely diagnosing disease recurrence and progression in T1 staged tumours.

Materials and methods : It was a prospective study done at the Department of Urology, Army Hospital (Research & Referral), New Delhi over a period of two years from June 2013 to May 2015. The study included 32 patients diagnosed to have T1 Transitional Cell Carcinoma of bladder on histopathology following the initial TURBT.

Results : In this study, 23 (71.86%) of the 32 specimen on initial TURBT were deep enough to include the muscularis propria for histopathological staging. In the early second TURBT, 12 (37.55%) patients had residual disease with 7 of them having gross residual disease. On histopathology 5 (15.6%) patients were found to have disease progression to muscle invasion (T2)

Conclusion : Early second TURBT (within 6 weeks of first TURBT) has a definitive role in detecting residual disease, early recurrence or progression in patients diagnosed to have T1 tumour on initial resection.

 


Keywords


T1 Bladder cancer, Early relook TURBT, early restaging TURBT

Full Text:

PDF

References


Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL et al. Global Cancer Facts and Figs. American Cancer Society. 2007; Atlanta: GA.

Herr HW and Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int. 2006; 97:1194–8.

Lachand AT, Texier J and Texier P. Surveillance and prognosis of “Ta” superficial tumors of the bladder. Homogeneous series of 138 cases followed for 1 to 18 years. Prog Urol. 2004;11:466–71.

Lachand AT, Texier J and Texier P. Surveillance and prognosis of “T1” superficial tumors of the bladder. Homogeneous series of 88 cases followed for 1 to 22 years. Prog Urol. 2001;11:472–7.

Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R and Vogeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 2003; 170:433–7.

Divrik RT, Yildirim U, Zorlu F and Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumours of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006;175:1641–4.

T. Divrik, U. Yildirim, A. Eroglu, F. Zorlu, H. Özen. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?. J Urol. 2006;175:1258-61.

J. Rigaud, G. Karam, G. Braud, P. Glemain, JM Buzelin, O Bouchot. Value of second endoscopic resection in stage T1 bladder tumors. Prog Urol. 2002;12:27-30.

Brauers, R. Buettner, G. Jakse. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol. 2001;165:808-10.

Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54:303–14.

Babjuk M. Transurethral resection of non–muscle-invasive bladder cancer. Eur Urol Suppl. 2009;8: 542–8.

Mariappan P, Zachou A, Grigor KM. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 2010;57:843-9.

Herr HW, Donat MS. Quality control in transurethral resection of bladder tumors. BJU Int. 2008; 102: 1242–6.

Schips L, Augustin H, Zigeuner RE, et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology. 2002;59:220–3.

Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 2006;97:1199–201.

Babjuk M. Second resection for non-muscle-invasive bladder carcinoma: Current role and future perspectives. Eur Urol. 2010;58:191–2.

Orsola A, Cecchini L, Raventos CX, Trilla E, Planas J, Landolfi S, et al. Risk factors for positive findings in patients with high grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and Bacilli Calmette Guerin therapy and the decision for a repeat TUR. BJU Int. 2010;105:202–7.

Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumours. J Urol. 1999;162:74–6.

Dutta SC, Smith JA, Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk non muscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001;166:490–3.

Klan R, Loy V and Huland. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol. 1991;146:316–8.

Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: A prospective randomised clinical trial. Eur Urol. 2010;58:185–90.

Serretta V, Ruggirello A, Dispensa N, Allegro R, Aragona F, Melloni D. Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumours selected for conservative treatment. J Urol. 2008;180:886–90.

Guevara A, Salomon L, Allory Y, et al. The role of tumor-free status in repeat resection before intravesical Bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer. J Urol. 2010;183: 2161–4.

Orsola A, Trias I, Ravento´s CX, Espanlo I, Cecchini L, Bucar S, et al. Initial high-grade T1 urothelial cell carcinoma: Feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol. 2005;48:231–8.

Orsola A, Cecchini L, Morote J, Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2008;54:303–14.

Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology. 2002;60:822–5.

Maurizio A. Brausi. Challenging the EAU Guidelines Regarding Early Repeat Transurethral Resection. European Urology supplements. 2011;10:5–7.


Refbacks

  • There are currently no refbacks.